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Abstract Some series of arylidene barbiturates and thiobarbiturates were evaluated for their
antibacterial, antioxidant, and urease inhibition activities. The arylidene barbiturates and
thiobarbiturates were tested for antimicrobial activity using the agar well diffusion technique
against 13 bacteria. The synthesized compounds (1a–g) were screened for antiurease and
antioxidant activities. The results showed that the synthesized compounds (1a–g) had
effective antiurease, antioxidant, and antibacterial activities.
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Introduction
Barbituric acids have attracted the attention of the pharmaceutical scientist for over 100 years
due to their therapeutic value [1]. Barbituric acid and its derivatives have exhibited biolog-
ical activities such as in antibacterial, hypotensive, and antisclerotics [2], sedative, hypnotic,
antispasmodic, anticonvulsant, and local anesthetic drugs [3, 4] as well as in anticancer [5],
anti-inflammatory [6], and matrix metalloproteinase inhibitors [7].
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In recent years, barbiturate and thiobarbiturate derivatives very much attracted consider-
able attention owing to their various biological effects such as inhibiting collagenase-3 [8]
matrix metalloproteinases [9], recombinant cytochrome P450 enzymes [10], methionine
aminopeptidase-1 [11], tyrosinase [12], and urease [13]. Also, antioxidant activity values
of some arylidene barbiturates have been studied [14].
Arylidene barbiturates are important members of the pyrimidine family. The major
importance of these compounds has been centered on their application as useful precursors
in the preparation of new heterocyclic bioactive molecules [15] and as potential selective
oxidizing agents [16] and for the unsymmetrical synthesis of disulphide [17]. Some of them
have been studied as nonlinear optical materials [18]. Due to their importance in the above-
mentioned, very different methods for barbituric acid synthesis were reported in the litera-
ture. Arylidene barbiturates may be synthesized by Knovenagel condensation reaction of
barbituric/thioubarbituric acid with various aldehydes [19–21]. The isolated products are
mono-substituted as well as di-substituted [22]. To achieve the formation of only one mono-
substituted condensation product, various catalysts has been investigated [1, 21, 23].
Free radicals are known to be the major cause of various chronic and degenerative
diseases, including aging, coronary heart disease, stroke, inflammation, diabetes mellitus,
and cancer [24, 25]. Reactive oxygen species (ROS) include free radicals such as superoxide
anion, hydroxyl radical, singlet oxygen, and hydrogen peroxide can cause cellular injuries
and initiate peroxidation of polyunsaturated fatty acids in biological membranes [26]. The
tissue injury caused by ROS may include DNA damage, protein damage, and important
enzymes in human body [27]. These events could consequently lead to the occurrence of
various free–radical-related diseases. Antioxidants are extensively studied for their capacity
to protect organisms and cells from damage that is induced by oxidative stress. Nowadays,
antioxidants arouse researchers’ interest in both medical plants and synthetic compounds.
Synthetic antioxidants, such as butylated hydroxyanisole (BHA), butylated hydroxytoluene
(BHT), and tert-butylhydroquinone, have been widely used in the food industry to prevent
oxidative deterioration, but BHA and BHT are suspected of being responsible for liver
damage and carcinogenesis [28]. Scientists in various disciplines have become more inter-
ested in new compounds, either synthesized or obtained from natural sources that could
provide active components to prevent or reduce the impact of oxidative stress on cells.
Urease (urea amidohydrolase; EC 3.5.1.5) is a nickel-containing metalloenzyme that cata-
lyzes the hydolysis of urea to form ammonia and carbamate [29]. The resulting carbamate
spontaneously decomposes to yield a second molecule of ammonia and carbon dioxide. It is
present in a variety of plants, algae, fungi, and bacteria in soil enzymes [30]. High concentra-
tions of ammonia arising from these reactions, as well as the accompanying pH elevation, have
important negative implications in medicine and agriculture [31, 32]. Urease is involved in the
pathogenesis of hepatic encephalopathy, hepatic coma urolithiasis, pyelonephritis, ammonia,
and urinary catheter encrustation [33]. It is also a major cause of pathologies induced by
Helicobacter pylori as this allows bacteria to survive at the low pH of the stomach and hence
plays an important role in producing peptic and gastric ulcers [34]. In the near past, a number of
compounds have been proposed as urease inhibitors to reduce environmental problems and
enhance the uptake of urea nitrogen by plants [35, 36]. Many urease inhibitors have been
investigated in the past decades, such as phosphorodiamidates, hydroxamic acid derivatives,
and imidazoles, but most of these compounds are too toxic or unstable to allow their use in vivo.
Thus, the search is still on for novel urease inhibitors with promising levels of activity [37].
In this study, we have investigated antioxidant, antimicrobial, and urease inhibition
activities of some arylidene barbituric acids (1a–g) derivatives. Urease inhibitors with
antioxidant and antimicrobial properties may be proved as hallmark for the development
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of new antiulcer drugs which will not only clear the H. pylori infection but also the induced
oxidative stress be redressed.
Materials and Methods
General
All chemicals and solvents are commercially available and were used after distillation or
treatment with drying agents. Antioxidant activities of samples were determined in a
spectrophotometer (UV-1240, Shimadzu, Japan).
Studied compounds 1a [38], 1b [11], 1c [39], 1d [11], 1e [40], 1f [41], and 1g [42] were
prepared by using literature procedures (Scheme 1; Table 1).
Microbial Strains
The synthesized compounds were tested individually against 13 gram-positive and gram-
negative bacteria species. The bacterial strains used in this study were obtained from the
American Type Culture Collection (ATCC) and were as follows: Enterobacter cloaceae
ATCC 13047, Enterococcus faecalis ATCC 29212, Salmonella typhimirium ATCC 14028,
Staphylococcus epidermidis ATCC 12228, Proteus vulgaris ATCC 13315, Yersinia pseudo-
tuberculosis ATCC 911, Staphylococcus aureus ATCC 25923, Pseudomanas aeruginosa
ATCC 27853, Klebsiella pneumoniae ATCC 13883, Bacillus subtilis ATCC6633,
Escherichia coli ATCC 35218, Listeria monocytogenes ATCC 7644, and E. faecalis ATCC
51299. All synthesized compounds were weighed and dissolved in dimethyl sulfoxide
(DMSO) to prepare extract stock solutions.
Antibacterial Activity with the Agar Well Diffusion Method
Antibacterial activity was screened by agar well diffusion method [43, 44]. Test bacteria was
cultivated overnight in Mueller Hinton Broth medium at 37°C. Then, Mueller Hinton Agar
plates were swabbed (sterile cotton swabs) with 100 μL of test bacteria culture which has
concentration OD625=0.08–0.1 (approximately 1×10
7–1×108 CFU/mL). Using the sterile
cork borer, the well (6 mm) was made into the each plate. The test substances were prepared
in DMSO which showed no zone of inhibition and acts as a negative control. The
Scheme 1 Studied compounds
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concentrations of the test substances were prepared as 30 mg/mL. Fifty microliters of the test
substances was added into the wells. Simultaneously, an antibiotic, ampicillin (60 mg/mL),
was used as positive control and were tested against the microorganisms. Twenty-five
microliters of the antibiotic was added into the wells. Then the plates were incubated at
37°C for 16–24 h. After the incubation period, the diameter of the inhibition zones of each
well was measured. Each experiment was performed in triplicate.
Antioxidant and Urease Enzyme Inhibition Activity
Cuprac-reducing antioxidant capacity of the some arylidene derivatives was determined
according to the method described by Apak et al. [45]. Urease inhibitory activity was
determined according to Van Slyke and Archilbald [46].
Result and Discussion
The anti-microbial activity of compounds 1a–g and ampicillin was assayed against the gram-
positive (G+) (E. faecalis ATCC 29212, S. epidermidis ATCC 12228, S. aureus ATCC 25923,
B. subtilisATCC6633, L.monocytogenesATCC 7644, and E. faecalisATCC 51299) and gram-
negative (G–) (E. cloaceae ATCC 13047, S. typhimirium ATCC 14028, P. vulgaris ATCC
13315, Y. pseudotuberculosis ATCC 911, P. aeruginosa ATCC 27853, K. pneumoniae ATCC
13883, and E. coli ATCC 35218) microorganisms. Anti-microbial activity of the studied
bacteria was qualitatively and quantitatively assessed by evaluating the presence of inhibition
zones and minimal inhibition concentration (MIC) values [47–50].
Four compounds (1a, 1e, 1f, 1g) showed anti-microbial activity against G+ and G– bacteria
tested, and the results are given in Tables 2 and 3. Four compounds (1a, 1e, 1f, 1g) were found
to be same active as ampicillin against almost all tested strains. The maximum inhibition zones
and MIC values for the bacterial strains that were sensitive to the studied arylidene barbiturates
compounds (1a–g) were in the range of 10–27 mm and from 10.30 to 650 μg/mL, respectively
(Table 3).
The results indicate that it is clear that the hydroxyl group of the aryl chain influenced the
broadening of the spectrum of anti-microbial activity and MIC values of the investigated
compounds. Decreasing of the activity was observed in the case of p–OH group in aryl chain
and due to replacing Owith S on barbiturate rings. Thioanalogues of arylidene barbiturates have
no antibacterial activity as compared with other studied barbiturates. On the other hand, when a
hydroxy group was present at o-position in ring-aryl, the activity increased accordingly in
arylidene barbiturates. Thus, increase in activity is probably due to the resonance effect of –OH
Table 1 Some arylidene
barbiturate derivatives used in
this study (1a–g)
Compounds R1 R2 R3 R4 R5
1a H H OH H O
1b OH H H H O
1c H H OH H S
1d OH H H H S
1e H H OH CH3 O
1f OH H OH CH3 O
1g H OH H CH3 O
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group that is more prominent at o-position than m-position and p-position. Above results show
that electron-donating groups like hydroxyl in o-position on the arylchain and oxygen in
carbonyl group on the barbiturate rings are responsible for the antibacterial activity of arylidene
barbiturates.
The reducing power has been used as one of the antioxidant capability indicators. There was
a correlation found between the reducing capabilities and substituents. The reason for the higher
Table 2 Antimicrobial screening data for the studied compounds (1a–g)
Zone of inhibition (mm)
1a 1b 1c 1d 1e 1f 1g AMP DMSO
E. cloaceae ATCC 13047 12 – – – 13 14 – – –
E. faecalis ATCC 29212 19 – – – 12 12 17 26 –
S. typhimirium ATCC 14028 13 – – – – 16 – 19 –
S. epidermidis ATCC 12228 25 – – – 18 20 16 a –
P. vulgaris ATCC 13315 26 – – – – 20 – 25 –
Y. pseudotuberculosis ATCC 911 – – – – 18 17 15 a –
S. aureus ATCC 25923 25 – – – 20 13 23 35 –
P. aeruginosa ATCC 27853 – – – – – – – 32 –
K. pneumoniae ATCC 13883 – – – – – 19 – – –
B. subtilis ATCC 6633 14 – – – 15 16 15 31 –
E. coli ATCC 35218 11 – – – – 19 – 15 –
L. monocytogenes ATCC 7644 27 – – – 15 17 19 27 –
E. faecalis ATCC 51299 20 – – – 11 10 15 28 –
AMP ampicillin (60 mg/mL) as positive control, DMSO negative control
a Not determined
Table 3 Minimum inhibition concentration values of the studied compounds (1a–g)
MIC values (μg/mL)
1a 1b 1c 1d 1e 1f 1g
E. cloaceae ATCC 13047 325.00 – – – 325.00 81.25 –
E. faecalis ATCC 29212 162.50 – – – 81.25 20.60 81.25
S. typhimirium ATCC 14028 650.00 – – – – 81.25 –
S. epidermidis ATCC 12228 40.12 – – – 81.25 40.12 81.25
P. vulgaris ATCC 13315 81.25 – – – – 81.25 –
Y. pseudotuberculosis ATCC 911 – – – – 325.00 162.50 650.00
S. aureus ATCC 25923 162.50 – – – 162.50 162.50 162.50
P. aeruginosa ATCC 27853 – – – – – – –
K. pneumoniae ATCC 13883 – – – – – 40.12 –
B. subtilis ATCC 6633 81.25 – – – 81.25 20.60 162.50
E. coli ATCC 35218 325.00 – – – 325.00 81.25 325.00
L. monocytogenes ATCC 7644 325.00 – – – 162.50 81.25 81.25
E. faecalis ATCC 51299 10.30 – – – 81.25 81.25 10.30
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reducing power capacity of the compounds can be explained by looking into the structure of
compounds. In our study, the barbiturates derivatives showed marked cupric ion (Cu+2)-
reducing ability. Cupric ion (Cu+2)-reducing ability of barbiturate derivatives is shown in
Table 4. Cupric ion (Cu+2)-reducing capability of barbiturates derivatives by cuprac method
was found to be concentration-dependent (25–100 μg/mL). Compounds 1b and 1f showed the
lowest cupric ion (Cu+2)-reducing capability (Table 3). Compounds 1g, 1e, and 1a exhibited the
moderate effect on reducing power. The highest reducing capacity was found for 1c and 1d
barbiturate derivatives. Thioanalogues of arylidene barbiturates have antioxidant activity as
compared with other studied barbiturates. Cupric ion (Cu+2)-reducing power of barbiturates
Table 4 Cupric ions reducing
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derivatives and BHT at the same concentration (100 μg/mL) exhibited the following order:
BHT>1c>1d>1g>1e>1a>1f>1b.
Certain synthetic compounds have shown potential urease inhibition such as hydroxy-
urea, flurofamide, and hydroxyamic acid; however, the in vivo use of some of these has been
prohibited because of their toxicity or instability; for instance, acetohydroxyamic acid has
been demonstrated to be teratogenic in rats [51]. The discovery of potent and safe urease
Table 5 The urease inhibitory
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inhibitors has been a very important area of pharmaceutical research due to the involvement
of urease in different pathological conditions.
Urease inhibitor activity of was given in Table 5. Table 5 shows that the arylidene barbiturate
derivatives are more potent than the standard inhibitor of urease, hydroxyurea, and thiourea.
Thiourea and hydroxyurea are the main examples of the substrate-like urease inhibitors. The
inhibition was increased with increasing barbiturate concentration. IC50 values for barbiturate
compounds were found to be 0.033–2.582 μM. Compounds 1g and 1e proved to be the most
potent showing an enzyme inhibition activity with an IC50=0.033–0.036 μM. The least active
compound 1a had an IC50=2.582 μM. All of the compounds showed high potent activity than
that of standard hydroxyurea (IC50=7.418 μM) and thiourea (IC50 = 8.825 μM). In the other
study, synthesized polyphenol compounds (IC50=22–43.8 μM) had a lower urease inhibitor
activity than in our study. The discovery that barbituric acid inhibits urease was made by Gray
et al., who observed that certain cyclic urea compounds (i.e., barbituric and thiobarbituric acids)
were capable of inhibiting bacterial and jack-bean urease [52, 53]. Tanaka et al. demonstrated
that some alpha hydroxyketone derivatives show urease inhibitory activity [54]. Xiao et al.
reported some synthesized pyrogallol and catechol derivatives as H. pylori urease inhibitors
[55]. Many synthetic and natural apple polyphenols have shown inhibitory activity against
urease activity [56]. Rauf et al. reported that some barbituric acid- and thiobarbituric acid-
derived sulfonamides were urease inhibitors [57]. In our study, the synthesized compounds can
be regarded as substrate-like inhibitors based on their structural similarity to the natural
substrate of urease, urea, and thiourea. Since all the synthesized barbiturate compounds promise
urease inhibitor activity, this may be due to their basic skeleton.
The presence of –S and –O of barbiturate derivatives isomers in this study may together
play a great role on urease inhibition activity.
Conclusions
In our study, some arylidene barbiturates have been synthesized, and their antibacterial,
antiurease, and antioxidant activities were evaluated. The results showed that all of arylidene
barbiturate derivatives exhibited antiurease and antioxidant activities. According to our results,
there is a correlation between antiurease, antibacterial, and antioxidant activities of compounds
and substituents. Among the synthesized compounds, compounds 1c and 1d were found to be
the most active reducing agent. Compounds 1g, 1e, 1d, and 1f were determined to be have the
highest antiurease activity. Also, compounds 1a, 1e, 1f, and 1g were showed to be the highest
antibacterial activity. These arylidene barbiturates can be used in agriculture and pharmacy
industries due to their excellent antibacterial, antiurease, and antioxidant activities.
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